CCM Quote, Financials, Valuation and Earnings

Dr Reddy's Laboratories has a net margin of -- compared to Concord Medical Services Holdings's net margin of 18.73%. Concord Medical Services Holdings's return on equity of -19.78% beat Dr Reddy's Laboratories's return on equity of 18.25%.

Concord Medical Services Holdings has a consensus price target of --, signalling upside risk potential of 37.77%. On the other hand Dr Reddy's Laboratories has an analysts' consensus of $14.42 which suggests that it could grow by 2.26%. Given that Concord Medical Services Holdings has higher upside potential than Dr Reddy's Laboratories, analysts believe Concord Medical Services Holdings is more attractive than Dr Reddy's Laboratories.

Concord Medical Services Holdings has a beta of -0.837, which suggesting that the stock is 183.673% less volatile than S&P 500. In comparison Dr Reddy's Laboratories has a beta of 0.326, suggesting its less volatile than the S&P 500 by 67.42%.

Concord Medical Services Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dr Reddy's Laboratories offers a yield of 0.68% to investors and pays a quarterly dividend of $0.10 per share. Concord Medical Services Holdings pays -- of its earnings as a dividend. Dr Reddy's Laboratories pays out 11.78% of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Concord Medical Services Holdings quarterly revenues are --, which are smaller than Dr Reddy's Laboratories quarterly revenues of $982M. Concord Medical Services Holdings's net income of -- is lower than Dr Reddy's Laboratories's net income of $183.9M. Notably, Concord Medical Services Holdings's price-to-earnings ratio is -- while Dr Reddy's Laboratories's PE ratio is 21.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Concord Medical Services Holdings is 0.71x versus 3.06x for Dr Reddy's Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech has a net margin of -- compared to Concord Medical Services Holdings's net margin of --. Concord Medical Services Holdings's return on equity of -19.78% beat Sinovac Biotech's return on equity of -1.05%.

Concord Medical Services Holdings has a consensus price target of --, signalling upside risk potential of 37.77%. On the other hand Sinovac Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that Concord Medical Services Holdings has higher upside potential than Sinovac Biotech, analysts believe Concord Medical Services Holdings is more attractive than Sinovac Biotech.

Concord Medical Services Holdings has a beta of -0.837, which suggesting that the stock is 183.673% less volatile than S&P 500. In comparison Sinovac Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Concord Medical Services Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Concord Medical Services Holdings pays -- of its earnings as a dividend. Sinovac Biotech pays out -328.35% of its earnings as a dividend.

Concord Medical Services Holdings quarterly revenues are --, which are smaller than Sinovac Biotech quarterly revenues of --. Concord Medical Services Holdings's net income of -- is lower than Sinovac Biotech's net income of --. Notably, Concord Medical Services Holdings's price-to-earnings ratio is -- while Sinovac Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Concord Medical Services Holdings is 0.71x versus 1.49x for Sinovac Biotech. Usually stocks with elevated PS ratios are considered overvalued.

111 has a net margin of -- compared to Concord Medical Services Holdings's net margin of -0.52%. Concord Medical Services Holdings's return on equity of -19.78% beat 111's return on equity of -21.67%.

Concord Medical Services Holdings has a consensus price target of --, signalling upside risk potential of 37.77%. On the other hand 111 has an analysts' consensus of -- which suggests that it could grow by 660.01%. Given that 111 has higher upside potential than Concord Medical Services Holdings, analysts believe 111 is more attractive than Concord Medical Services Holdings.

Concord Medical Services Holdings has a beta of -0.837, which suggesting that the stock is 183.673% less volatile than S&P 500. In comparison 111 has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.823%.

Concord Medical Services Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 111 offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Concord Medical Services Holdings pays -- of its earnings as a dividend. 111 pays out -- of its earnings as a dividend.

Concord Medical Services Holdings quarterly revenues are --, which are smaller than 111 quarterly revenues of $534.8M. Concord Medical Services Holdings's net income of -- is lower than 111's net income of -$2.8M. Notably, Concord Medical Services Holdings's price-to-earnings ratio is -- while 111's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Concord Medical Services Holdings is 0.71x versus 0.03x for 111. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of -- compared to Concord Medical Services Holdings's net margin of -45.49%. Concord Medical Services Holdings's return on equity of -19.78% beat Zai Lab's return on equity of -33.29%.

Concord Medical Services Holdings has a consensus price target of --, signalling upside risk potential of 37.77%. On the other hand Zai Lab has an analysts' consensus of $54.59 which suggests that it could grow by 90.74%. Given that Zai Lab has higher upside potential than Concord Medical Services Holdings, analysts believe Zai Lab is more attractive than Concord Medical Services Holdings.

Concord Medical Services Holdings has a beta of -0.837, which suggesting that the stock is 183.673% less volatile than S&P 500. In comparison Zai Lab has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.742%.

Concord Medical Services Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Concord Medical Services Holdings pays -- of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend.

Concord Medical Services Holdings quarterly revenues are --, which are smaller than Zai Lab quarterly revenues of $106.5M. Concord Medical Services Holdings's net income of -- is lower than Zai Lab's net income of -$48.4M. Notably, Concord Medical Services Holdings's price-to-earnings ratio is -- while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Concord Medical Services Holdings is 0.71x versus 6.95x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.